Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial
Human drug compounding, Food and Drug Administration (2024) Compounding when drugs are on FDAs drug shortages list, Food and Drug Administration (2024) FDA drug shortages: Semaglutide injection, Food and Drug Administration FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, Food and Drug Administration (2024) Ozempic, DailyMed (2024) Find out if your insurance covers Ozempic, Novo Nordisk FDA warns patients and health care professionals not to use compounded drugs from Fullerton Wellness, Food and Drug Administration (2024) Company statement: Novo Nordisk escalates legal actions to safeguard patients from potentially harmful compounded semaglutide drugs, Novo Nordisk (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
There are some of these drugs approved for chronic weight management, such as Wegovy, while others, such as Ozempic , are approved for treating type 2 diabetes but may also be prescribed off-label for weight loss in adults
For example, a 2023 RCT revealed that only a subset of adults experienced substantial alterations in gut microbiota and metabolic markers following a standardized probiotic, with responses closely associated with baseline community composition (573)
Over the first six months, they lost an average of 12.3kg
